162 related articles for article (PubMed ID: 38686627)
1. DFMO inhibition of neuroblastoma tumorigenesis.
Gandra D; Mulama DH; Foureau DM; McKinney KQ; Kim E; Smith K; Haw J; Nagulapally A; Saulnier Sholler GL
Cancer Med; 2024 May; 13(9):e7207. PubMed ID: 38686627
[TBL] [Abstract][Full Text] [Related]
2. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
Makena MR; Cho HE; Nguyen TH; Koneru B; Verlekar DU; Hindle A; Kang MH; Reynolds CP
Pediatr Blood Cancer; 2018 Dec; 65(12):e27447. PubMed ID: 30251395
[TBL] [Abstract][Full Text] [Related]
4. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
5. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
Lozier AM; Rich ME; Grawe AP; Peck AS; Zhao P; Chang AT; Bond JP; Sholler GS
Oncotarget; 2015 Jan; 6(1):196-206. PubMed ID: 25415050
[TBL] [Abstract][Full Text] [Related]
6. DFMO Carbon Dots for Treatment of Neuroblastoma and Bioimaging.
Paudyal S; Vallejo FA; Cilingir EK; Zhou Y; Mintz KJ; Pressman Y; Gu J; Vanni S; Graham RM; Leblanc RM
ACS Appl Bio Mater; 2022 Jul; 5(7):3300-3309. PubMed ID: 35771033
[TBL] [Abstract][Full Text] [Related]
7. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
[TBL] [Abstract][Full Text] [Related]
8. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
9. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
[TBL] [Abstract][Full Text] [Related]
10. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.
Maser T; Rich M; Hayes D; Zhao P; Nagulapally AB; Bond J; Saulnier Sholler G
Cancer Med; 2017 Jun; 6(6):1341-1352. PubMed ID: 28429453
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
12. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
13. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
Eslin D; Sankpal UT; Lee C; Sutphin RM; Maliakal P; Currier E; Sholler G; Khan M; Basha R
Mol Carcinog; 2013 May; 52(5):377-86. PubMed ID: 22213339
[TBL] [Abstract][Full Text] [Related]
14. Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513.
Coulter DW; McGuire TR; Sharp JG; McIntyre EM; Dong Y; Wang X; Gray S; Alexander GR; Chatuverdi NK; Joshi SS; Chen X; Vennerstrom JL
BMC Cancer; 2016 Nov; 16(1):867. PubMed ID: 27821095
[TBL] [Abstract][Full Text] [Related]
15. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
[TBL] [Abstract][Full Text] [Related]
16. Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro.
Singh RK; Dorf L; DeMartino A; Illenye S; Koto K; Currier EA; Ashikaga T; Kim KK; Brard L; Sholler GL
Cancer Biol Ther; 2011 Jun; 11(12):1036-45. PubMed ID: 21532338
[TBL] [Abstract][Full Text] [Related]
17. alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model.
Takahashi Y; Mai M; Nishioka K
Int J Cancer; 2000 Jan; 85(2):243-7. PubMed ID: 10629084
[TBL] [Abstract][Full Text] [Related]
18. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
[TBL] [Abstract][Full Text] [Related]
19. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
